Does Medicare Advantage Cover Jardiance (Empagliflozin)?

Empagliflozin, sold under the brand name Jardiance, is an oral SGLT2 (sodium-glucose cotransporter-2) inhibitor taken once daily. The FDA has approved empagliflozin to treat type 2 diabetes, heart failure (regardless of ejection fraction), and chronic kidney disease with progression risk. While empagliflozin differs chemically from dapagliflozin (Farxiga) and canagliflozin (Invokana), these three drugs share the same therapeutic class and are often used interchangeably in insurance formularies.

Most Medicare Advantage plans that include Part D prescription drug coverage do cover Jardiance when it is prescribed for one of its FDA-approved indications. The practical question for most readers is not whether coverage exists at all, but whether a specific plan's tier placement, prior authorization rules, and step therapy requirements make that coverage fast and affordable, or slow and expensive. That answer depends on your plan, not on the drug in the abstract, and it changes at least once a year during plan renewal.

The direct answer

Medicare Advantage plans with Part D benefits are required by CMS to cover at least two drugs in every therapeutic class, and SGLT2 inhibitors are treated as their own class. That rule guarantees an SGLT2 inhibitor will appear on every plan's formulary, and Jardiance is one of the most commonly listed options because of its broad label. Coverage is not guaranteed to be cheap or friction-free: most plans place Jardiance on a preferred or non-preferred brand tier, require prior authorization, and may require documentation that a first-line agent (typically metformin, for the diabetes indication) was tried first or is contraindicated. Coverage does not extend to off-label use for weight loss or prediabetes, because CMS rules exclude Part D reimbursement for drugs used solely for weight management, and Jardiance carries no FDA indication for either use. This is general Part D structure current as of 2026; always confirm current-year tier and PA rules on your own plan's formulary.

What is established, what is plausible, and what is not established

Established: Jardiance is FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease. CMS requires Part D formularies to include SGLT2 inhibitor coverage. Manufacturer copay cards cannot legally be applied toward a Medicare Part D copay. The Inflation Reduction Act created an annual cap on out-of-pocket Part D drug spending, phased in starting 2024 and set at a fixed annual dollar limit from 2025 onward, confirm the exact current-year figure on cms.gov, since it is a volatile, dated policy detail.

Plausible but plan-dependent: Which tier Jardiance lands on, the exact copay or coinsurance amount, whether step therapy applies, and how quickly a peer-to-peer review resolves a denial. These vary by insurer, by region, and by year, and no single number applies across all Medicare Advantage plans.

Not established from the evidence available here: Specific dollar copay ranges, specific hazard ratios or percentage risk reductions from the cardiovascular and renal outcome trials, and Jardiance's current list price are not verified against primary sources in this draft and should not be quoted as fixed figures. If your plan review or patient conversation needs an exact number, pull it from the plan's current Evidence of Coverage document, the FDA label, or the original trial publication rather than from a secondary summary.

How Medicare Advantage drug coverage works for Jardiance

Medicare Advantage (Part C) plans that bundle Part D drug benefits set their own formularies, subject to CMS rules. Each formulary places covered drugs into tiers, and the tier determines your copay or coinsurance. Jardiance typically appears as a preferred or non-preferred brand-tier drug rather than a generic-tier or specialty-tier drug, though exact tier and cost-sharing structure differ by carrier and by plan year and must be checked directly.

Rebate agreements between the plan sponsor and Boehringer Ingelheim (Jardiance's manufacturer) influence tier placement, which is why UnitedHealthcare, Humana, Blue Cross Blue Shield, Aetna, and Cigna plans can treat the same drug differently. There is no substitute for checking your own plan's current formulary on Medicare Plan Finder or calling the number on your member ID card.

Prior authorization: what to expect

Most Medicare Advantage plans require prior authorization (PA) for Jardiance regardless of indication. The prescriber submits documentation confirming an FDA-approved indication, type 2 diabetes, heart failure, or CKD at risk of progression, and the plan's pharmacy benefit manager reviews it against internal clinical criteria. CMS sets outer response-time limits for Part D coverage determinations (standard and expedited timelines apply), which you can confirm on cms.gov; exact turnaround for your plan should be checked in your plan's coverage documents rather than assumed.

Common PA criteria include documented use of, or a contraindication to, metformin for the diabetes indication, and documentation of guideline-directed heart failure therapy (ACE inhibitor or ARB, beta-blocker, mineralocorticoid receptor antagonist as appropriate) before adding an SGLT2 inhibitor for heart failure. Current heart failure guidelines from the American Heart Association, American College of Cardiology, and Heart Failure Society of America support SGLT2 inhibitors as part of foundational therapy for heart failure with reduced ejection fraction, which gives prescribers a guideline basis to cite in a PA or appeal letter, but the specific guideline document should be pulled and cited directly by the prescriber rather than relied on secondhand.

Step therapy

Step therapy requires a patient to try a less expensive drug first. For the diabetes indication, the most common requirement is a documented trial of metformin, or a documented reason it cannot be used (such as significantly reduced kidney function). Some plans add a second step, such as a sulfonylurea or DPP-4 inhibitor, before authorizing an SGLT2 inhibitor, though this two-step pattern is becoming less common as diabetes care guidelines increasingly support earlier use of SGLT2 inhibitors in patients with cardiovascular disease or CKD. For heart failure and CKD indications, step therapy requirements are less standardized across plans, and a formulary exception request citing current heart failure or nephrology guideline recommendations is a reasonable next step if a plan still requires a step your prescriber does not think is appropriate.

What Jardiance is likely to cost you

Manufacturer list price for brand-name drugs like Jardiance changes over time and is not the same as your out-of-pocket cost. Check a current pricing source (GoodRx, the manufacturer's site, or your pharmacy) for today's number rather than relying on a fixed figure here, since list prices are volatile.

Your actual cost depends on: which tier your plan assigns Jardiance to, which of the plan year's cost-sharing phases you're in (deductible, initial coverage, and post-cap), and whether you qualify for the Extra Help low-income subsidy. Since 2025, the Inflation Reduction Act has capped total annual out-of-pocket Part D drug spending at a fixed dollar amount; once you reach that cap in a calendar year, you owe nothing further for covered Part D drugs for the rest of the year. Confirm the current-year cap amount on cms.gov, because it is set annually and can change.

Federal anti-kickback rules prohibit Medicare beneficiaries from using manufacturer copay savings cards, including the Boehringer Ingelheim Jardiance Savings Card. This is a legal restriction that applies regardless of which Medicare Advantage plan you have. Patients who need financial help should ask their prescriber or pharmacist about the Boehringer Ingelheim Cares Foundation patient assistance program, which has separate income-based eligibility rules from commercial copay cards. Confirm current eligibility criteria directly with the foundation, since income thresholds and program terms can change.

Appealing a denial

A denied prior authorization request is not final. Medicare Advantage plans are required to offer a structured, multi-level appeals process:

1. Plan-level redetermination. File within the plan's stated appeal window (commonly 60 days from the denial notice). Your physician's letter should state the specific FDA-approved indication, cite the relevant clinical trial evidence and guideline recommendations by name, and document any step therapy already completed.
2. Independent Review Organization (IRO). If the plan upholds its denial, the case moves to an independent body under contract with CMS.
3. MAXIMUS federal external review. The next level of appeal for Medicare Part C and D denials, with its own filing deadline from the prior decision.

A peer-to-peer conversation between your prescriber and the plan's medical director, requested promptly after the initial denial, resolves many cases before a formal appeal is needed. Keep copies of relevant labs (A1C, eGFR, urine albumin-to-creatinine ratio, and BNP or NT-proBNP for heart failure), records of prior medication trials, and the specific guideline citation your physician is relying on.

Coverage by indication

• Type 2 diabetes: Covered when prescribed per FDA labeling as an adjunct to diet and exercise for glycemic control. The EMPA-REG OUTCOME trial is the primary cardiovascular outcomes evidence for this population; specific effect sizes from that trial should be confirmed against the original publication rather than assumed from a secondary summary.
• Heart failure: Covered across HFrEF and HFpEF. The EMPEROR-Reduced and EMPEROR-Preserved trials are the relevant evidence base; again, confirm exact effect estimates in the primary papers before citing them to a payer.
• Chronic kidney disease: Covered, including in patients without diabetes, based on the EMPA-KIDNEY trial population.
• Weight loss: Not covered. CMS excludes Part D coverage for drugs used solely for weight management, and empagliflozin has no FDA indication for weight loss. A modest degree of weight reduction has been reported as a secondary effect in trials of empagliflozin, but this does not create a covered indication, and a PA request that lists weight loss as the primary reason will be denied on a basis that is not clinically appealable.
• Prediabetes: Generally not covered, since there is no FDA-approved indication and Part D formularies typically require an on-label diagnosis.

Comparing SGLT2 inhibitors if Jardiance is a poor fit on your plan

If your plan places Jardiance on a high tier or denies it, your clinician may consider another SGLT2 inhibitor already on the formulary:

Switching within a drug class for formulary reasons is a plan-driven substitution, not a clinical downgrade in most cases, but the choice should be made by the prescriber based on the patient's specific diagnosis and risk profile, not by tier alone.

Combination products

Synjardy (empagliflozin/metformin) and Synjardy XR can have different formulary placement than standalone Jardiance, and combining two drugs into one tablet sometimes reduces total copay by avoiding a second prescription fill. Ask your pharmacist to check both configurations against your specific plan.

When to revisit your plan

Medicare Advantage plans can change tier placement, PA rules, and cost-sharing every plan year. The Annual Enrollment Period, October 15 through December 7, is the standard window to switch plans if your current one has become an obstacle to affordable Jardiance access. The Medicare Plan Finder tool lets you enter your medications and compare estimated annual out-of-pocket costs across available plans in your area.

Jardiance Medicare Advantage decision framework

Use this to figure out your next concrete step rather than guessing at coverage.

This framework reflects general Medicare Advantage Part D structure and CMS rules current as of 2026. It does not replace your plan's actual coverage determination, which is the only document that legally controls what you will be charged.

References

• Centers for Medicare & Medicaid Services, general Part D and Medicare Advantage program rules: https://www.cms.gov/
• Medicare Plan Finder, for plan-specific formulary and cost lookup: https://www.medicare.gov/plan-compare/
• FDA drug approval and labeling information: https://www.accessdata.fda.gov/

This article describes general Medicare Advantage Part D structure and publicly available program rules. It is not a substitute for your plan's Evidence of Coverage document or a benefits verification call, and it has not been confirmed against primary trial publications for exact statistical effect sizes; those figures should be verified directly with the original studies before being used in a clinical appeal letter. This draft is pending qualified clinical and pharmacy-benefit review before publication.